rp 48740 has been researched along with tetradecanoylphorbol acetate in 1 studies
| Studies (rp 48740) | Trials (rp 48740) | Recent Studies (post-2010) (rp 48740) | Studies (tetradecanoylphorbol acetate) | Trials (tetradecanoylphorbol acetate) | Recent Studies (post-2010) (tetradecanoylphorbol acetate) |
|---|---|---|---|---|---|
| 24 | 0 | 0 | 31,050 | 61 | 2,217 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bousseau, A; Fauci, AS; Poli, G; Weissman, D | 1 |
1 other study(ies) available for rp 48740 and tetradecanoylphorbol acetate
| Article | Year |
|---|---|
A platelet-activating factor antagonist, RP 55778, inhibits cytokine-dependent induction of human immunodeficiency virus expression in chronically infected promonocytic cells.
Topics: Cell Line; Chloramphenicol O-Acetyltransferase; Cytokines; Fluorescent Antibody Technique; Granulocyte-Macrophage Colony-Stimulating Factor; HIV Reverse Transcriptase; HIV-1; Humans; Interleukin-6; Kinetics; Monocytes; Platelet Activating Factor; Pyridines; Recombinant Proteins; RNA Processing, Post-Transcriptional; RNA-Directed DNA Polymerase; RNA, Messenger; RNA, Viral; Tetradecanoylphorbol Acetate; Thiazoles; Transcription, Genetic; Transfection; Tumor Necrosis Factor-alpha | 1993 |